{
    "nct_id": "NCT04126733",
    "official_title": "An Open-label, Single-arm, Phase II Study of Regorafenib and Nivolumab in Patients With Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC)",
    "inclusion_criteria": "* Histological or cytological confirmed advanced, metastatic, or progressive pMMR/MSS adenocarcinoma of colon or rectum\n* Participant must have progressed or be intolerant to prior systemic chemotherapy including fluoropyrimidines, irinotecan, oxaliplatin, anti-vascular endothelial growth factor (VEGF) therapy, and, if extended rat sarcoma viral oncogene homolog (RAS) wild type, an anti-epidermal growth factor receptor (EGFR) therapy. Exceptions may apply\n* Participants must have adequate organ and marrow function defined by protocol-specified laboratory tests\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Measurable disease as determined by response evaluation criteria in solid tumors (RECIST) v1.1\n* Provision of recently obtained tumor tissue as per protocol specified requirement\n* Anticipated life expectancy greater than 3 months\n* Be able to swallow and absorb oral tablets\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participants with Mismatch repair deficient (dMMR) / microsatellite instable-high (MSI-H) colorectal cancer\n* Prior therapy with regorafenib, anti-programmed cell death protein 1 (PD-1), programmed cell death protein 1 ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of immunotherapy to treat cancer\n* Presence of active central nervous system (CNS) metastases; participants with stable CNS disease or previously treated lesions are eligible for study entry\n* Poorly controlled hypertension, defined as a blood pressure consistently above 150/90 mmHg despite optimal medical management\n* Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks) within 6 months before the start of study medication. Active pulmonary emboli or deep vein thrombosis that are significant or not adequately controlled on anticoagulation regimen\n* Any hemorrhage or bleeding event â‰¥ National Cancer Institute - Common terminology criteria for adverse events (NCI-CTCAE) Grade 3 within 28 days prior to the start of study medication\n* Participants with an active, known or suspected autoimmune disease\n* History of interstitial lung disease or pneumonitis\n* Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection\n* Other protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}